EXCITING PRESS

This Fierce Growth Stock Is a Monster Value Right Now

This Fierce Growth Stock Is a Monster Value Right Now

The The Motley Fool details InMode as a company likely to outperform the market over the next few years.

“Over the past three years, its trailing 12-month revenue grew by 174%, reaching nearly $378M, whereas its net income popped by 304%. Nonetheless, it recently experienced a bump in the road when both its top and bottom lines contracted sharply compared to the prior three-month period. Management pointed to the global supply chain and shipment prices as the reasons for its contracting margins, both of which it expects to continue. But that doesn’t seem to matter much anymore, now that a few workarounds are in place. On July 12, the company gave a sneak peek into its anticipated Q2 earnings and it has opted to raise its guidance for 2022 from a high end of $425 million in revenue to a new high end of $435 million.”

Read the article here

InMode INMD stock on Mad Money Lightening Round

InMode INMD stock on Mad Money Lightening Round

Mad Money host Jim Cramer rings the lightning round bell to answer callers’ stock questions, including InMode’s INMD stock. “InMode [sic] is a situation that’s a very good situation, but the mercurial nature of this market is not letting this InMode bottom. I like InMode.”

Watch the segment here

InMode (INMD) featured on Mad Money with Jim Cramer

InMode (INMD) featured on Mad Money with Jim Cramer

Mad Money host Jim Cramer answers callers’ stock questions during the Lightning Round, including InMode.

Watch the clip here.

Can Medical Aesthetics Firm InMode Keep Its Picture-Perfect Growth Streak Alive?

Can Medical Aesthetics Firm InMode Keep Its Picture-Perfect Growth Streak Alive?

Investor’s Business Daily reporter Allison Gatlin writes that “InMode stock is looking picture perfect” as the stock (Nasdaq: INMD) has managed to stay at the top of the IBD 50. So, what’s driving the outperformance? “Aesthetics, in general, are growing because of a variety of factors,” Needham analyst Mike Matson told Investor’s Business Daily, noting social media, the Zoom culture and an aging population have played a role in the recent medical aesthetics boom. InMode’s technology leads to “better results with less invasive treatment,” Matson added, “that technology is unique and that’s what’s been the primary driver.”

Read the full article here.

Charts suggest InMode stock is worth buying into weakness, says Jim Cramer

Charts suggest InMode stock is worth buying into weakness, says Jim Cramer

CNBC’s Mad Money host Jim Cramer and Bob Lang review four growth stocks, including shares of medical technology company InMode.

Read the full article here.

-->

How can we help?

Please select a topic below related to your inquiry.

Find a clinic
Questions about treatments
Questions about our technologies or workstations
General inquiries email or call 1.855.411.2639

GET STARTED

Which technology is right for you?

Contact Us
Contact Us

Contact Us